证券代码：300119 证券简称：瑞普生物 公告编号：2025-100 瑞普生物股份有限公司 关于取得新兽药注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《兽药管理条例》和《兽药注册办法》的规定，瑞普生物股份有限公司 （以下简称"公司""瑞普生物"）及下属分子公司天津瑞普生物技术股份有限 公司空港经济区分公司、瑞普（保定）生物药业有限公司 2 款新兽药产品近日获 农业农村部批准，详情如下： 原体流行菌株，能够显著减少免疫猪群肺炎病变损伤；副猪嗜血杆菌抗原覆盖主 要流行血清型 4 型、5 型菌株，可有效降低或阻断相应菌株感染。该产品采用无 血清全悬浮细胞培养、细菌高密度发酵和高效的浓缩纯化等先进技术，实现制苗 抗原的精纯制备；开发相对效力标准和菌体蛋白浓度制苗标准，实现工艺稳定、 均一可控；搭配兼顾多种抗原组合安全性和免疫效果的水性佐剂，显著降低副反 应发生率。该疫苗免疫后 4 周可产生免疫力，免疫持续期可达 5 个月，实现"一 针三防"，大幅简化临床免疫程序，助力养殖场提升免疫效率、节省人力成本、 减少猪群临床免疫应激。 该产品的成功获批 ...

Group 1 - The animal vaccine sector experienced a decline of 0.47%, ranking among the top losers in concept sectors, with notable declines from companies like BioShares, Luo Niu Shan, and Tian Kang Bio [1] - Among the stocks in the animal vaccine sector, 10 stocks saw price increases, with Hengtong Co., Hai Zheng Pharmaceutical, and Hai Li Bio leading the gains at 3.67%, 0.69%, and 0.48% respectively [1] - The main capital outflow from the animal vaccine sector today was 87 million yuan, with 14 stocks experiencing net outflows, led by Luo Niu Shan with a net outflow of 95.06 million yuan [2] Group 2 - The top net inflow stocks in the animal vaccine sector included BioShares, Da Bei Nong, and Zhong Mu Co., with net inflows of 46.84 million yuan, 6.50 million yuan, and 3.83 million yuan respectively [2][3] - The capital outflow leaderboard for the animal vaccine sector included Luo Niu Shan, Hengtong Co., and Rui Pu Bio, with respective outflows of 95.06 million yuan, 11.49 million yuan, and 7.66 million yuan [2][3] - The trading activity showed that Luo Niu Shan had a turnover rate of 16.52%, while other companies like Hengtong Co. and Tian Kang Bio had turnover rates of 3.51% and 1.98% respectively [2][3]

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

Core Insights - The core viewpoint of the articles highlights the significant growth and strategic positioning of the company, Ruipu Biological, in the animal health industry, aiming to become a leader in both China and globally [2][3]. Group 1: Financial Performance - In 2024, the company is projected to achieve revenue exceeding 3 billion yuan, with a 14% year-on-year growth in the first three quarters of 2025, reaching 2.5 billion yuan and a net profit of 360 million yuan, marking a 46% increase [2]. - The company completed a targeted issuance of 1.336 billion yuan in 2021 to support its industrial chain upgrade [2]. Group 2: Industry Positioning - Ruipu Biological is the first publicly listed company in the A-share market focused on veterinary medicine, holding the largest market share in the domestic industry [2]. - The company has established a comprehensive industrial chain covering 12 large-scale production bases across 8 provinces, with products exported to over 50 countries and regions [2]. Group 3: Research and Development - The company invests over 200 million yuan annually in R&D, accounting for 7.76% of its revenue, and has built 6 national-level innovation platforms [2]. - As of now, the company has obtained 121 new veterinary drug registration certificates and 330 authorized patents, with a significant milestone being the clinical approval of the world's first mRNA vaccine for food animals in 2025 [2]. Group 4: Future Strategy - The company aims to become the number one in China's animal health industry and among the top five globally, focusing on synthetic biology, mRNA vaccines, and genetic engineering [3]. - Plans include expanding global reach, particularly in the "Belt and Road" markets, and creating a comprehensive ecosystem encompassing vaccines, pharmaceuticals, health products, and medical services [3].

Core Viewpoint - RuiPu Bio, the first A-share listed company focused on veterinary medicine, aims for significant growth during the "14th Five-Year Plan" period, leveraging capital market operations and strategic investments in biomanufacturing [1][2] Financial Performance - In 2024, the company expects revenue to exceed 3 billion yuan, with a 14% year-on-year growth in the first three quarters of 2025, achieving 2.5 billion yuan in revenue and a net profit of 360 million yuan, marking a 46% increase [1] - The pet supply chain revenue reached 633 million yuan in 2024, reflecting a 37.66% year-on-year growth [1] Industry Positioning - RuiPu Bio holds the largest market share in the domestic veterinary medicine sector and has established a comprehensive industry chain covering 12 large-scale production bases across 8 provinces [1] - The company exports products to over 50 countries and regions worldwide [1] Research and Development - The company invests over 200 million yuan annually in R&D, accounting for 7.76% of its revenue, and has established 6 national-level innovation platforms [2] - RuiPu Bio has received 121 new veterinary drug registration certificates and holds 330 authorized patents [2] - In 2025, the company is set to receive clinical approval for the world's first mRNA vaccine for food animals, targeting porcine epidemic diarrhea virus [2] Strategic Goals - The company aims to become the leading player in China's animal health industry and rank among the top five globally, focusing on synthetic biology, mRNA vaccines, and genetic engineering [2] - RuiPu Bio plans to expand its global footprint, particularly in the "Belt and Road" markets, and to innovate within the "vaccine-drug-healthcare-medical service" ecosystem [2]

证券日报网讯 12月15日晚间，瑞普生物发布公告称，公司第六届董事会第一次（临时）会议审议通过 《关于聘任高级管理人员的议案》等多项议案。 （文章来源：证券日报） ...

每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ 每经AI快讯，瑞普生物（SZ 300119，收盘价：19.18元）12月15日晚间发布公告称，公司第六届2025年 第六次董事会临时会议于2025年12月15日在公司会议室以现场会议方式召开。会议审议了《关于选举第 六届董事会董事长的议案》等文件。 2024年1至12月份，瑞普生物的营业收入构成为：兽用生物制品占比43.12%，兽用药物占比33.86%，宠 物供应链占比20.63%，其他占比2.38%。 截至发稿，瑞普生物市值为89亿元。 （记者 王晓波） ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-098 二、董事会会议审议情况 1、审议通过了《关于选举第六届董事会董事长的议案》 经审议，同意选举李守军先生为公司董事长，任期三年，自本次董事会审议 通过之日起至第六届董事会任期届满之日止。 简历详见公司同日在深圳证券交易所网站（http://www.szse.cn）及巨潮资讯 网（http://www.cninfo.com.cn）披露的《关于董事会换届完成暨聘任高级管理人 员及证券事务代表的公告》。 第六届董事会第一次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日召开 2025 年第六次临时股东会以及职工代表大会，完成董事会换届选举工作。第六届董事 会第一次（临时）会议于 2025 年 12 月 15 日在公司会议室以现场会议方式召开。 经全体董事一致同意，本次会议通知当日以口头方式向全体董事送达。公司应出 席董事 9 人，实际出席董事 9 人，参与表决董事 9 人。本次 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-099 瑞普生物股份有限公司 关于董事会换届完成暨 聘任高级管理人员及证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日召开 2025 年第六次临时股东会以及职工代表大会，完成董事会换届选举工作。同日，公司 召开第六届董事会第一次（临时）会议选举产生了第六届董事会董事长、第六届 董事会各专门委员会成员，聘任了公司高级管理人员、证券事务代表。具体公告 如下： 一、第六届董事会组成情况 1、第六届董事会成员 董事长：李守军先生 董事：徐雷先生、刘爱玲女士、朱秀同先生、李睿女士 职工代表董事：刘国柱先生 独立董事：董义春先生、王凯先生、李娅女士 第六届董事会成员任期自 2025 年第六次临时股东会以及职工代表大会审议 通过之日起三年。 公司第六届董事会中兼任公司高级管理人员以及由职工代表担任的董事人 数总计未超过公司董事总数的二分之一，独立董事的人数未低于公司董事总数的 三分之一，符合相关法规及《公司章程》的规 ...

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 受瑞普生物股份有限公司（以下简称"公司"）聘请，北京市通商律师事务 所指派律师（以下简称"本所律师"）出席了公司 2025 年第六次临时股东会（以 下简称"本次股东会"），并依据《中华人民共和国公司法》（以下简称"《公 司法》"）、《上市公司股东会规则》、《深圳证券交易所上市公司股东会网络 投票实施细则》等法律、法规、规章、规范性文件及《瑞普生物股份有限公司章 程》（以下简称"《公司章程》"）的规定，对公司本次股东会召集及召开程序、 出席会议的人员资格、召集人资格、提案审议情况、股东会的表决方式、表决程 序和表决结果等重要事项的合法性进行了审核和见证 ...